• Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated...
    3 KB (188 words) - 00:48, 14 May 2023
  • Thumbnail for Tumor necrosis factor
    Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy...
    49 KB (6,233 words) - 07:30, 6 November 2024
  • Rituximab Ublituximab CD23 Gomiliximab Lumiliximab CD40 Teneliximab Toralizumab CD62L/L-selectin Aselizumab CD80 Galiximab CD147/Basigin Gavilimomab...
    7 KB (299 words) - 13:45, 27 April 2024
  • Democratic Education Conference, an annual academic and youth conference Toralizumab (IDEC 131), an antibody and an immunosuppressive drug The sponsor name...
    591 bytes (108 words) - 17:53, 28 May 2021
  • Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy...
    5 KB (305 words) - 05:22, 23 October 2024
  • Spartalizumab† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412§...
    38 KB (4,316 words) - 10:24, 26 August 2024
  • (INN) Toprol-XL Topsyn topterone (INN) toquizine (INN) Tora Toradol toralizumab (USAN) torapsel (USAN) torasemide (INN) torbafylline (INN) torcetrapib...
    7 KB (373 words) - 02:05, 25 April 2024
  • Thumbnail for List of therapeutic monoclonal antibodies
    Tomuzotuximab mab humanized Epidermal growth factor receptor (EGFR), HER1 cancer Toralizumab mab humanized CD154 (CD40L) rheumatoid arthritis, lupus nephritis etc...
    137 KB (4,083 words) - 21:25, 19 October 2024
  • Thumbnail for Tumor necrosis factor superfamily
    Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy...
    8 KB (316 words) - 13:53, 10 September 2024
  • Thumbnail for TNF receptor superfamily
    Oxelumab Ruplizumab Tabalumab Tavolixizumab Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy...
    8 KB (501 words) - 13:55, 10 September 2024